<DOC>
	<DOCNO>NCT02050529</DOCNO>
	<brief_summary>Severe Hypertension pregnancy demand urgent treatment high mortality &amp; morbidity obstetric patient . Hydralazine , commonly use agent , cause sudden hypotension tachycardia . Labetalol combine α β block effect lacks side effect . Cochrane systematic review could include three trial comparison hydralazine labetalol . All three sample size range 20-60 obstetric , include 19-30 pregnant woman . This review could conclude comparative effect due insufficient data suggest trial compare hydralazine nifedipine labetalol , report severe persistent hypertension adverse feto-maternal effect . OBJECTIVES:1 ) To compare efficacy labetalol versus hydralazine control pregnancy relate severe hypertension.2 ) To compare adverse maternal fetal effect two drug . 3 ) Furthermore , develop risk assessment model response treatment , term patient disease characteristic . STUDY DESIGN : Randomized controlled trial . SETTING &amp; DURATION OF STUDY : Gynaecology Unit I , Civil hospital Karachi period 1 year . METHODS : Total one hundred eighty patient , severe hypertension ( systolic blood pressure ( SBP ) ≥160 and/or diastolic blood pressure ( DBP ) ≥110 mm Hg ) great 28 week pregnancy upto72 hour delivery , enrol . In group 90 patient allocate intravenous labetalol hydralazine use simple random sampling . Primary outcome measure lower SBP &lt; 160 mm Hg DBP &lt; 110 mm Hg severe persistent hypertension . In addition maternal hypotension , tachycardia , bradycardia , adverse effect fetal heart , still birth neonatal bradycardia measure . EXPECTED OUTCOME : Efficacy side effect labetalol hydralazine , population determine . Assessment model response treatment , help choose drug well efficacy minimal side effect profile different patient disease profile .</brief_summary>
	<brief_title>Randomized Clinical Trial Labetalol Versus Hydralazine Severe Hypertension Obstetric Patients .</brief_title>
	<detailed_description>Study Hypothesis : This non inferiority trial study hypothesis labetalol equal good hydralazine . Patients diagnose severe hypertension ( repeat measurement BP 15 minute rest ) , admit 24 hour period emergency , meet inclusion criterion , include . One hundred eighty patient enrol informed consent randomly allocate treatment arm 1:1 randomization simple random allocation . All eligible pregnant post partum woman systolic blood pressure ≥160mm Hg diastolic BP ≥110 mm Hg , repeat measurement 15 minute rest , admit emergency outpatient department , invite participation study . They enrol informed consent . Drug treatment assign use simple random sampling . INCLUSIONS CRITERIA Pregnant post partum patient systolic blood pressure ≥160mm Hg diastolic BP ≥110 mm Hg , repeat measurement blood pressure 15 minute rest , meet follow inclusion criterion include . 1 . Pregnancy = &gt; 28 wks gestational hypertension , severe preeclampsia , chronic hypertension , chronic hypertension superimpose preeclampsia , eclampsia unclassified hypertension . 2 . Postpartum patient , upto 72 hour delivery , diagnose gestational hypertension , severe preeclampsia , chronic hypertension , chronic hypertension superimpose preeclampsia , eclampsia unclassified hypertension . 3 . Patients singleton multiple pregnancy . 4 . Patients age parity . EXCLUSION CRITERIA 1 ) Patients asthma . 2 ) Patients cardiac failure heart block . 3 ) Patients pace device place type cardiac arrhythmia . DATA COLLECTION INSTRUMENT Data record case report form ( CRF ) . Group A receive intravenous ( IV ) labetalol bolus dos administer 2 minute , 10 minute interval . Initially dose 20mg administer , require repeat increment 40 mg,80 mg,80mg,80mg every 10 minute till SBP become &lt; 160 DBP &lt; 110 mm Hg , upto maximum total dose 300mg ( total 5 bolus dos ) .During time pulse blood pressure check every 10 minute . Failure reduce SBP &lt; 160 DBP &lt; 110 consecutive maximum 5 bolus ( 300mg ) label severe persistent hypertension.In case patient give alternate treatment hydralazine 5 mg slow intravenous bolus , 2 minute blood pressure rechecked 20 minute . If SBP still ≥160 DBP ≥110 mm Hg another bolus 5 mg hydralazine repeat consultation medical/cardiovascular/critical care specialist seek . Blood pressure pulse record 10 minute interval till blood pressure reduce threshold level ( SBP &lt; 160 diastolic &lt; 110 mm Hg ) .Once level achieve monitoring continued every 15 minute interval two hour , every 30 minute interval 1 hour thereafter hourly interval next 4 hour . Group B ( control ) receive intravenous hydralazine bolus dose 5 mg administer 2 minute , 20 minute interval . Pulse blood pressure check every 10 minute interval . If SBP threshold 160 mm Hg DBP 110 mm Hg still reach 20 minute , second bolus repeat . Similarly 20 minute SBP still ≥160 DBP ≥110 mm Hg , third dose give . If SBP DBP threshold still exceed 20 minute similarly 4th dose 5 mg give . Failure reduce SBP &lt; 160 DBP &lt; 110 consecutive maximum 4 bolus ( total 20 mg ) label severe persistent hypertension.Once blood pressure reduce threshold level , pulse blood pressure monitor similar group A . Failure reduce SBP &lt; 160 DBP &lt; 110 consecutive maximum 4 bolus ( total 20 mg ) label severe persistent hypertension ; consider treatment failure . In case , patient give alternate treatment labetalol 20 mg slow intravenous bolus 2 minute , blood pressure rechecked 10 minute . If SBP still ≥160 DBP ≥110 mm Hg , another bolus 40 mg labetalol repeat emergency consultation medical /cardiovascular /critical care specialist seek . Our use alternate treatment severe persistent hypertension group keep line recent American College Obstetricians Gynaecologist 's committee opinion 2011 recommendation . Cardiotocography ( CTG ) do pregnant woman admission repeat 2 hour initiation therapy . Primary outcome measure lower SBP &lt; 160 mm Hg DBP &lt; 110 mm Hg schedule dosage allocate treatment ( primary end point study ) severe persistent hypertension i.e treatment failure . Secondary outcome measure adverse drug effect i.e maternal hypotension , tachycardia , bradycardia , palpitation , headache , nausea vomiting , dizziness , bronchospasm , oliguria , adverse effect fetal heart , neonatal bradycardia . In study arm , patient 's monitoring decision delivery pregnant patient take accord department protocol consistent standard recommendation . OPERATIONAL DEFINITIONS 1 . Gestational hypertension diagnose BP ≥140/90mm Hg 20 week pregnancy previously normotensive woman , proven antenatal record . 2 ) . Preeclampsia define BP ≥ 140/90 mm Hg along proteinuria ≥ 1+ dipstick previously normotensive , non-proteinuric woman , proven antenatal record . 3 ) . Chronic Hypertension diagnose history preexist hypertension &amp; detect persistent elevation BP≥140/90 mm Hg . prior 20 week pregnancy . 4 ) . Severe preeclampsia define BP ≥160/110 alongwith proteinuria≥1+ dipstick without one follow feature i.e headache , visual disturbance , upper right quadrant/epigastric pain , pulmonary oedema , elevate alanine aminotransfrease ( ALT ) , raise creatinine , hemolysis , thrombocytopenia , intrauterine growth restriction ( IUGR ) previously normotensive non proteinuric woman , proven antenatal record . 5 ) Eclampsia diagnose generalize tonic clonic seizure woman hypertensive disorder attributable cause . 6 ) Efficacy define lower systolic BP &lt; 160mm Hg diastolic BP &lt; 110 mm Hg . 7 ) Severe persistent hypertension define SBP≥160 DBP≥ 110 mm Hg administration consecutive maximum ( 4 5 ) dos allocate drug treatment . 8 ) Maternal hypotension define systolic BP &lt; 90mm Hg diastolic BP &lt; 60 mm Hg . 9 ) Maternal tachycardia define heart rate &gt; 100b/m absence fever &amp; cardiovascular disease . 10 ) Normal Cardiotocograph ( CTG ) Will define follow 4 feature ) Baseline heart rate 110-160beats/minute ii ) Variability &gt; 5-25 beats/minutes iii ) aleast 2 acceleration &gt; 15 b/m last for≥15 second . iv ) No deceleration . 11 ) Adverse effect fetal heart rate ( FHR ) define ) presence type deceleration without uterine contraction ii ) Reduced variability &lt; 5 b/m &gt; 40 minute , iii ) Variable &amp; late deceleration , presence uterine contraction iii ) FHR &lt; 110b/m &gt; 160b/m detect CTG 2 hour start treatment , baseline normal CTG admission . 12 ) Placental abruption define clinical feature uterine tenderness evidence retroplacental clot delivery . 13 ) Oliguria define urinary output &lt; 30 ml/hr ≥4 hour . 14 ) Neonatal bradycardia define heart rate &lt; 100b/m DATA ANALYSIS PLAN : Data enter analyzed SPSS version 17 . Continuous variable i.e age , parity , gestation , SBP , DBP , MAP randomization present mean ± SD whereas mean reduction MAP , number bolus antihypertensive , mean dose achieve desire level control analyze student 's test . Qualitative variable i.e control BP , severe persistent hypertension , maternal hypotension , tachycardia , bradycardia , headache , palpitation , nausea vomiting , dizziness , oliguria , placental abruption , adverse effect fetal heart rate , still birth , neonatal bradycardia , caesarean section , Apgar score &lt; 7 1 5 minute neonatal intensive care admission analyze chi square , require , Fischer 's exact test . For analyze adverse effect FHR , patient admission CTG show fetal bradycardia &lt; 110 b/m , tachycardia &gt; 160b/m , variability &lt; 5b/m &gt; 40 minute , variable late deceleration , exclude stratification do normal CTG CTG subtle abnormality normal baseline FHR 110-160b/m enrolement i.e ) Absence acceleration ii ) reduce variability &lt; 5 beats/min &lt; 40 minute iii ) early deceleration presence uterine contraction . Adverse effect FHR study antenatal woman neonatal outcome ( Apgar , neonatal bradycardia ) study patient deliver within 24 hour enrolement . Furthermore assessment model base logistic regression develop response either drug term patient &amp; disease characteristic i.e ethnicity , age group , parity group , socioeconomic status ( income group ) , gestational age group , pregnancy status whether antepartum post partum disease characteristic i.e type hypertension blood pressure level admission . Multinomial logistic regression apply Odds ratio calculate factor .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Pre-Eclampsia</mesh_term>
	<mesh_term>Eclampsia</mesh_term>
	<mesh_term>Hypertension , Pregnancy-Induced</mesh_term>
	<mesh_term>Labetalol</mesh_term>
	<mesh_term>Hydralazine</mesh_term>
	<criteria>INCLUSIONS CRITERIA Pregnant post partum patient systolic blood pressure ≥160mm Hg diastolic BP ≥110 mm Hg , repeat measurement blood pressure 15 minute rest , meet follow inclusion criterion include . 1 . Pregnancy great 28 wks ( gestational age determine ultrasound prior 20 week unavailable uterine size first prenatal visit last menstrual period ) gestational hypertension , severe preeclampsia , chronic hypertension , chronic hypertension superimpose preeclampsia , eclampsia unclassified hypertension . 2 . Postpartum patient , upto 72 hour delivery , diagnose gestational hypertension , severe preeclampsia , chronic hypertension , chronic hypertension superimpose preeclampsia , eclampsia unclassified hypertension . 3 . Patients singleton multiple pregnancy . 4 . Patients age parity . 1 . Patients asthma . 2 . Patients cardiac failure heart block . 3 . Patients pace device place type cardiac arrhythmia .</criteria>
	<gender>Female</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Hypertension , Pregnancy induce</keyword>
	<keyword>Pre-eclampsia</keyword>
	<keyword>Eclampsia</keyword>
	<keyword>Labetalol</keyword>
	<keyword>Hydralazine</keyword>
</DOC>